O papel da Medicina de Família e Comunidade no uso medicinal de Cannabis

Autores

  • Rubens Cavalcanti Freire da Silva Universidade de Pernambuco– Recife (PE), Brasil / Secretaria Municipal de Saúde de Recife, Recife (PE), Brasil. https://orcid.org/0000-0002-8111-9067
  • Georgia Leal Cesar de Albuquerque Secretaria Municipal de Saúde de Jaboatão dos Guararapes, Programa Médicos pelo Brasil – Jabotão dos Guararapes (PE), Brasil. https://orcid.org/0000-0003-3491-5607

DOI:

https://doi.org/10.5712/rbmfc18(45)3632

Palavras-chave:

Cannabis, Maconha Medicinal, Medicina de Família e Comunidade, Atenção primária à saúde.

Resumo

O uso medicinal de Cannabis tem registros históricos que datam aproximadamente de 3.000 anos a.C. e persistiu em diversos momentos da história. Os estudos clínicos sobre esse uso iniciaram-se na década de 1960, porém as pesquisas foram interrompidas em razão da política proibicionista do uso de Cannabis, reconhecido como droga ilícita. O retorno das pesquisas nos anos 1990 ratificou os efeitos terapêuticos dessa planta, tornando-a um potencial recurso a ser ofertado pelo Sistema Único de Saúde, com acesso pela Atenção Primária à Saúde. Com este ensaio, propomos refletir sobre o papel da Medicina de Família e Comunidade enquanto especialidade relevante no manejo terapêutico de Cannabis medicinal. Essa reflexão parte dos princípios da especialidade e do Sistema Único de Saúde, assim como é fundamentada nas evidências clínicas quanto ao uso medicinal da maconha.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Biografia do Autor

Georgia Leal Cesar de Albuquerque, Secretaria Municipal de Saúde de Jaboatão dos Guararapes, Programa Médicos pelo Brasil – Jabotão dos Guararapes (PE), Brasil.

Médica de Família e Comunidade pelo Programa de Residência em Medicina de Família e Comunidade da Secretaria Municipal de Saúde do Recife. Atua como médica pelo Programa Médicos Pelo Brasil como médica bolsista 2022-2024

Referências

Mechoulam R. Conversation with Raphael Mechoulam. Addiction 2007;102(6):887-93. https://doi.org/10.1111/j.1360-0443.2007.01795.x DOI: https://doi.org/10.1111/j.1360-0443.2007.01795.x

Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry 2006;28(2):153-7. https://doi.org/10.1590/s1516-44462006000200015 DOI: https://doi.org/10.1590/S1516-44462006000200015

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev 2010;62(4):588-631. https://doi.org/10.1124/pr.110.003004 DOI: https://doi.org/10.1124/pr.110.003004

Sanchez-Ramos J. The entourage effect of the phytocannabinoids. Ann Neurol 2015;77(6):1083. https://doi.org/10.1002/ana.24402 DOI: https://doi.org/10.1002/ana.24402

Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290(13):1757-62. https://doi.org/10.1001/jama.290.13.1757 DOI: https://doi.org/10.1001/jama.290.13.1757

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362(9395):1517-26. https://doi.org/10.1016/S0140-6736(03)14738-1 DOI: https://doi.org/10.1016/S0140-6736(03)14738-1

Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10(4):417-24. https://doi.org/10.1191/1352458504ms1048oa DOI: https://doi.org/10.1191/1352458504ms1048oa

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-9. https://doi.org/10.1212/01.wnl.0000176753.45410.8b DOI: https://doi.org/10.1212/01.wnl.0000176753.45410.8b

Hoggart B, Ratcliffe S, Ehler E, Simpson KH, Hovorka J, Lejčko J, et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol 2015;262(1):27-40. https://doi.org/10.1007/s00415-014-7502-9 DOI: https://doi.org/10.1007/s00415-014-7502-9

Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391(10125):1085-96. https://doi.org/10.1016/S0140-6736(18)30136-3 DOI: https://doi.org/10.1016/S0140-6736(18)30136-3

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018;378(20):1888-97. https://doi.org/10.1056/NEJMoa1714631 DOI: https://doi.org/10.1056/NEJMoa1714631

Almog S, Aharon‐Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. Eur J Pain 2020;24(8):1505-16. https://doi.org/10.1002/ejp.1605 DOI: https://doi.org/10.1002/ejp.1605

Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. JAMA Neurol 2020;77(5):613-21. https://doi.org/10.1001/jamaneurol.2020.0073 DOI: https://doi.org/10.1001/jamaneurol.2020.0073

Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002;35(2):57-61. https://doi.org/10.1055/s-2002-25028 DOI: https://doi.org/10.1055/s-2002-25028

Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003;64(4):459-65. https://doi.org/10.4088/jcp.v64n0417 DOI: https://doi.org/10.4088/JCP.v64n0417

Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, et al Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010;70(5):656-63. https://doi.org/10.1111/j.1365-2125.2010.03743.x DOI: https://doi.org/10.1111/j.1365-2125.2010.03743.x

Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J 2011;13(8):455-8. PMID: 21910367

Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25(1):121-30. https://doi.org/10.1177/0269881110379283 DOI: https://doi.org/10.1177/0269881110379283

Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2(3):e94. https://doi.org/10.1038/tp.2012.15 DOI: https://doi.org/10.1038/tp.2012.15

Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013;11(10):1276-80.e1. https://doi.org/10.1016/j.cgh.2013.04.034 DOI: https://doi.org/10.1016/j.cgh.2013.04.034

McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 2018;175(3):225-31. https://doi.org/10.1176/appi.ajp.2017.17030325 DOI: https://doi.org/10.1176/appi.ajp.2017.17030325

Bahorik AL, Sterling SA, Campbell CI, Weisner C, Ramo D, Satre DD. Medical and non-medical marijuana use in depression: longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization. J Affect Disord 2018;241:8-14. https://doi.org/10.1016/j.jad.2018.05.065 DOI: https://doi.org/10.1016/j.jad.2018.05.065

Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol 2019;33(9):1141-8. https://doi.org/10.1177/0269881119858306 DOI: https://doi.org/10.1177/0269881119858306

Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology 2019;44(8):1398-405. https://doi.org/10.1038/s41386-019-0333-8 DOI: https://doi.org/10.1038/s41386-019-0333-8

Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 2019;176(11):911-22. https://doi.org/10.1176/appi.ajp.2019.18101191 DOI: https://doi.org/10.1176/appi.ajp.2019.18101191

de Faria SM, de Morais Fabrício D, Tumas V, Castro PC, Ponti MA, Hallak JE, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. J Psychopharmacol 2020;34(2):189-96. https://doi.org/10.1177/0269881119895536 DOI: https://doi.org/10.1177/0269881119895536

Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 2020;31(11):1553-60. https://doi.org/10.1016/j.annonc.2020.07.020 DOI: https://doi.org/10.1016/j.annonc.2020.07.020

Carneiro H. Drogas: a história do proibicionismo. São Paulo: Autonomia Literária; 2018. 541 p.

Barros A, Peres M. Proibição da maconha no Brasil e suas raízes históricas escravocratas. Periferia 2011;3(2):2-21. https://doi.org/10.12957/periferia.2011.3953 DOI: https://doi.org/10.12957/periferia.2011.3953

Gusso G, Lopes JMC, Dias LC. Tratado de Medicina de Família e Comunidade. 2ª ed. Porto Alegre: Artmed; 2018.

Freeman T, McWhinney IR. McWhinney’s textbook of family medicine. 4ª ed.New York: Oxford University Press; 2016. 520 p.

Brandão M. Em Marcha: maconha e a reversão de um estigma. Praça Rev Discente Pós-grad Em Sociol UFPE 2017;1(1):47–69.

Brasil. Projeto de lei n.º 399-A, de 2015 (do Sr. Fábio Mitidieri) [Internet]. 2015 [acessado em 20 jun. 2022]. Disponível em: em: https://www.camara.leg.br/proposicoesWeb/prop_mostrarintegra;jsessionid=node01vstr0jr2h1es9r68blsy6yh22291316.node0?codteor=2027392&filename=Avulso+-PL+399/2015

Downloads

Publicado

2023-07-05

Como Citar

1.
Silva RCF da, Albuquerque GLC de. O papel da Medicina de Família e Comunidade no uso medicinal de Cannabis. Rev Bras Med Fam Comunidade [Internet]. 5º de julho de 2023 [citado 18º de julho de 2024];18(45):3632. Disponível em: https://rbmfc.org.br/rbmfc/article/view/3632

Edição

Seção

Perspectivas

Plaudit